Immunome Inc [IMNM] stock is trading at $6.20, down -0.16%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMNM shares have lost -0.64% over the last week, with a monthly amount drifted -32.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on April 02, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $23. Previously, Stephens started tracking the stock with Overweight rating on November 08, 2024, and set its price target to $30. On May 31, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $24 on April 30, 2024. Guggenheim initiated its recommendation with a Buy and recommended $35 as its price target on April 15, 2024. Leerink Partners started tracking with a Outperform rating for this stock on January 29, 2024, and assigned it a price target of $30. In a note dated December 19, 2023, Wedbush initiated an Outperform rating and provided a target price of $12 on this stock.
Immunome Inc [IMNM] stock has fluctuated between $5.15 and $21.72 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $6.20 at the most recent close of the market. An investor can expect a potential return of 389.19% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 9.04M for the trailing twelve months, which represents a drop of -28.44%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -33.82%, Pretax Profit Margin comes in at -32.4%, and Net Profit Margin reading is -32.4%. To continue investigating profitability, this company’s Return on Assets is posted at -1.22, Equity is -1.25 and Total Capital is -1.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.87 points at the first support level, and at 5.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.41, and for the 2nd resistance point, it is at 6.63.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 4.08. On the other hand, the Quick Ratio is 4.08, and the Cash Ratio is 2.64. Considering the valuation of this stock, the price to sales ratio is 59.63, the price to book ratio is 2.21.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Mar 25 ’25 when 7800.0 shares were purchased. President and CEO, SIEGALL CLAY B completed a deal on Mar 26 ’25 to buy 0.14 million shares. Meanwhile, Director BIENAIME JEAN JACQUES bought 7000.0 shares on Mar 24 ’25.
